Details for New Drug Application (NDA): 218645
✉ Email this page to a colleague
The generic ingredient in ZELVYSIA is sapropterin dihydrochloride. There are three drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the sapropterin dihydrochloride profile page.
Summary for 218645
| Tradename: | ZELVYSIA |
| Applicant: | Aucta |
| Ingredient: | sapropterin dihydrochloride |
| Patents: | 0 |
Suppliers and Packaging for NDA: 218645
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ZELVYSIA | sapropterin dihydrochloride | POWDER;ORAL | 218645 | ANDA | Aucta Pharmaceuticals, Inc. | 73289-0070 | 73289-0070-2 | 30 PACKET in 1 CARTON (73289-0070-2) / 1 POWDER, FOR SOLUTION in 1 PACKET (73289-0070-1) |
| ZELVYSIA | sapropterin dihydrochloride | POWDER;ORAL | 218645 | ANDA | Aucta Pharmaceuticals, Inc. | 73289-0071 | 73289-0071-2 | 30 PACKET in 1 CARTON (73289-0071-2) / 1 POWDER, FOR SOLUTION in 1 PACKET (73289-0071-1) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;ORAL | Strength | 100MG/PACKET | ||||
| Approval Date: | Apr 29, 2025 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;ORAL | Strength | 500MG/PACKET | ||||
| Approval Date: | Apr 29, 2025 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
